Key Points
- Insider sale: Mittie Doyle sold 3,970 shares of Avalo Therapeutics on April 6 at an average price of $18.01 for $71,499.70 under a pre-arranged Rule 10b5-1 trading plan, cutting her position by 52.29% to 3,622 shares.
- Recent insider activity: Doyle also sold 679 shares on April 1 and 25,492 shares on March 16, bringing her recent proceeds from these three trades to about $494,060.
- Company/analyst context: AVTX opened at $14.41 (market cap ≈ $328.4M, 1‑year range $3.39–$20.72) and carries a consensus analyst rating of “Moderate Buy” with a $44.20 price target.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 3,970 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This represents a 52.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mittie Doyle also recently made the following trade(s):
- On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00.
- On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80.
Avalo Therapeutics Stock Performance
Shares of AVTX opened at $14.41 on Thursday. The stock has a market capitalization of $328.40 million, a PE ratio of -2.51 and a beta of 0.93. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72. The company's 50-day simple moving average is $15.54 and its 200-day simple moving average is $16.09.
Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. On average, sell-side analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on AVTX. Guggenheim began coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a "buy" rating and a $50.00 price target on the stock. Mizuho raised shares of Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Wall Street Zen raised shares of Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Sunday, March 29th. Finally, BTIG Research reissued a "buy" rating and set a $40.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.20.
Check Out Our Latest Stock Analysis on Avalo Therapeutics
Hedge Funds Weigh In On Avalo Therapeutics
Several hedge funds have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC increased its stake in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock valued at $17,150,000 after purchasing an additional 382,300 shares during the last quarter. Nantahala Capital Management LLC increased its stake in Avalo Therapeutics by 24.1% in the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock valued at $15,697,000 after purchasing an additional 240,000 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Avalo Therapeutics by 4.5% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company's stock valued at $19,087,000 after purchasing an additional 44,837 shares during the last quarter. Caligan Partners LP increased its stake in Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company's stock valued at $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics in the third quarter valued at approximately $10,390,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
